List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3335562/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prospective evaluation of a breast-cancer risk model integrating classical risk factors and polygenic risk in 15 cohorts from six countries. International Journal of Epidemiology, 2022, 50, 1897-1911.	1.9	43
2	Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans. Leukemia, 2022, 36, 119-125.	7.2	10
3	Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis. Leukemia, 2022, 36, 1058-1065.	7.2	3
4	Evaluating educational interventions to increase breast density awareness among Latinas: A randomized trial in a Federally Qualified Health Center. Cancer, 2022, 128, 1038-1047.	4.1	5
5	Rare germline copy number variants (CNVs) and breast cancer risk. Communications Biology, 2022, 5, 65.	4.4	6
6	Common variants in breast cancer risk loci predispose to distinct tumor subtypes. Breast Cancer Research, 2022, 24, 2.	5.0	15
7	Breast Density Knowledge and Awareness Among Latinas in a Low-Resource Setting. Journal of the American College of Radiology, 2022, 19, 155-161.	1.8	3
8	Breast Cancer Screening Strategies for Women With <i>ATM, CHEK2</i> , and <i>PALB2</i> Pathogenic Variants. JAMA Oncology, 2022, 8, 587.	7.1	36
9	Associations of history of vaccination and hospitalization due to infection with risk of monoclonal B-cell lymphocytosis. Leukemia, 2022, , .	7.2	1
10	Prevalence of heavy chain MGUS by race and family history risk groups using a high-sensitivity screening method. Blood Advances, 2022, 6, 3746-3750.	5.2	2
11	Genome-wide and transcriptome-wide association studies of mammographic density phenotypes reveal novel loci. Breast Cancer Research, 2022, 24, 27.	5.0	15
12	Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota. Blood Cancer Journal, 2022, 12, 67.	6.2	13
13	Genome-wide interaction analysis of menopausal hormone therapy use and breast cancer risk among 62,370 women. Scientific Reports, 2022, 12, 6199.	3.3	2
14	Genome-wide meta-analysis of monoclonal gammopathy of undetermined significance (MGUS) identifies risk loci impacting IRF-6. Blood Cancer Journal, 2022, 12, 60.	6.2	2
15	Association of breast cancer risk, density, and stiffness: global tissue stiffness on breast MR elastography (MRE). Breast Cancer Research and Treatment, 2022, 194, 79-89.	2.5	9
16	Distinct Reproductive Risk Profiles for Intrinsic-Like Breast Cancer Subtypes: Pooled Analysis of Population-Based Studies. Journal of the National Cancer Institute, 2022, 114, 1706-1719.	6.3	14
17	Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea. Journal of the National Cancer Institute, 2021, 113, 1105-1108.	6.3	5
18	Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk. Journal of the National Cancer Institute, 2021, 113, 329-337.	6.3	45

#	Article	IF	CITATIONS
19	Background Parenchymal Uptake on Molecular Breast Imaging and Breast Cancer Risk: A Cohort Study. American Journal of Roentgenology, 2021, 216, 1193-1204.	2.2	11
20	Impact of Personalized Genetic Breast Cancer Risk Estimation With Polygenic Risk Scores on Preventive Endocrine Therapy Intention and Uptake. Cancer Prevention Research, 2021, 14, 175-184.	1.5	11
21	CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. British Journal of Cancer, 2021, 124, 842-854.	6.4	5
22	Association of mammographic density measures and breast cancer "intrinsic―molecular subtypes. Breast Cancer Research and Treatment, 2021, 187, 215-224.	2.5	11
23	Genetic Variations and Health-Related Quality of Life (HRQOL): A Genome-Wide Study Approach. Cancers, 2021, 13, 716.	3.7	3
24	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nature Communications, 2021, 12, 1078.	12.8	19
25	A Population-Based Study of Genes Previously Implicated in Breast Cancer. New England Journal of Medicine, 2021, 384, 440-451.	27.0	414
26	Association of Daily Alcohol Intake, Volumetric Breast Density, and Breast Cancer Risk. JNCI Cancer Spectrum, 2021, 5, pkaa124.	2.9	2
27	Sequencing at lymphoid neoplasm susceptibility loci maps six myeloma risk genes. Human Molecular Genetics, 2021, 30, 1142-1153.	2.9	2
28	Genetic Predictors of Chemotherapy-Induced Peripheral Neuropathy from Paclitaxel, Carboplatin and Oxaliplatin: NCCTG/Alliance N08C1, N08CA and N08CB Study. Cancers, 2021, 13, 1084.	3.7	11
29	Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients. International Journal of Cancer, 2021, 149, 327-336.	5.1	3
30	Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families. Blood, 2021, 137, 2046-2056.	1.4	16
31	Automated Quantitative Measures of Terminal Duct Lobular Unit Involution and Breast Cancer Risk—Letter. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 797-797.	2.5	1
32	Automated percent mammographic density, mammographic texture variation, and risk of breast cancer: a nested case-control study. Npj Breast Cancer, 2021, 7, 68.	5.2	15
33	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. American Journal of Human Genetics, 2021, 108, 1190-1203.	6.2	6
34	Risk of Late-Onset Breast Cancer in Genetically Predisposed Women. Journal of Clinical Oncology, 2021, 39, 3430-3440.	1.6	21
35	Mammographic Variation Measures, Breast Density, and Breast Cancer Risk. American Journal of Roentgenology, 2021, 217, 326-335.	2.2	9
36	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. Breast Cancer Research, 2021, 23, 86.	5.0	7

#	Article	IF	CITATIONS
37	Risk of Breast Cancer Among Carriers of Pathogenic Variants in Breast Cancer Predisposition Genes Varies by Polygenic Risk Score. Journal of Clinical Oncology, 2021, 39, 2564-2573.	1.6	47
38	Mendelian randomisation study of smoking exposure in relation to breast cancer risk. British Journal of Cancer, 2021, 125, 1135-1145.	6.4	9
39	Genetic determinants of multiple myeloma risk within the Wnt/beta-catenin signaling pathway. Cancer Epidemiology, 2021, 73, 101972.	1.9	Ο
40	Genetic insights into biological mechanisms governing human ovarian ageing. Nature, 2021, 596, 393-397.	27.8	183
41	Deep Learning Predicts Interval and Screening-detected Cancer from Screening Mammograms: A Case-Case-Control Study in 6369 Women. Radiology, 2021, 301, 550-558.	7.3	15
42	Fully Automated Volumetric Breast Density Estimation from Digital Breast Tomosynthesis. Radiology, 2021, 301, 561-568.	7.3	22
43	Deep-LIBRA: An artificial-intelligence method for robust quantification of breast density with independent validation in breast cancer risk assessment. Medical Image Analysis, 2021, 73, 102138.	11.6	29
44	Factors Associated With Severe COVID-19 Infection Among Persons of Different Ages Living in a Defined Midwestern US Population. Mayo Clinic Proceedings, 2021, 96, 2528-2539.	3.0	16
45	Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 623-642.	2.5	19
46	Simplified Breast Risk Tool Integrating Questionnaire Risk Factors, Mammographic Density, and Polygenic Risk Score: Development and Validation. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 600-607.	2.5	14
47	Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis. Scientific Reports, 2021, 11, 19787.	3.3	2
48	Association of EDARV370A with breast density and metabolic syndrome in Latinos. PLoS ONE, 2021, 16, e0258212.	2.5	5
49	Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast. Journal of Clinical Oncology, 2021, 39, 3918-3926.	1.6	22
50	Incorporating Robustness to Imaging Physics into Radiomic Feature Selection for Breast Cancer Risk Estimation. Cancers, 2021, 13, 5497.	3.7	4
51	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	21.4	120
52	Breast Density Awareness, Knowledge, and Attitudes Among US Women: National Survey Results Across 5 Years. Journal of the American College of Radiology, 2020, 17, 391-404.	1.8	26
53	Breast Cancer Risk and Use of Nonsteroidal Anti-inflammatory Agents After a Benign Breast Biopsy. Cancer Prevention Research, 2020, 13, 967-976.	1.5	9
54	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. American Journal of Human Genetics, 2020, 107, 837-848.	6.2	39

#	Article	IF	CITATIONS
55	Free Light Chain Assay Drift: Potential for Misdiagnosis?. journal of applied laboratory medicine, The, 2020, 5, 1411-1413.	1.3	15
56	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 2020, 52, 572-581.	21.4	265
57	Evaluation of LIBRA Software for Fully Automated Mammographic Density Assessment in Breast Cancer Risk Prediction. Radiology, 2020, 296, 24-31.	7.3	21
58	Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. Scientific Reports, 2020, 10, 9688.	3.3	2
59	The CCND1 c.870G risk allele is enriched in individuals of African ancestry with plasma cell dyscrasias. Blood Cancer Journal, 2020, 10, 39.	6.2	4
60	Coinherited genetics of multiple myeloma and its precursor, monoclonal gammopathy of undetermined significance. Blood Advances, 2020, 4, 2789-2797.	5.2	20
61	Transcriptomeâ€wide association study of breast cancer risk by estrogenâ€receptor status. Genetic Epidemiology, 2020, 44, 442-468.	1.3	32
62	The Association of Modifiable Breast Cancer Risk Factors and Somatic Genomic Alterations in Breast Tumors: The Cancer Genome Atlas Network. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 599-605.	2.5	7
63	A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. Nature Communications, 2020, 11, 312.	12.8	30
64	Tumor mutational load predicts time to first treatment in chronic lymphocytic leukemia (CLL) and monoclonal Bâ€cell lymphocytosis beyond the CLL international prognostic index. American Journal of Hematology, 2020, 95, 906-917.	4.1	17
65	Assessing Vitamin D and Mammographic Breast Density in Alaskan Women. Clinics and Practice, 2020, 10, 1253.	1.4	3
66	Polygenic Risk Score and Risk of Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocytosis (MBL), and MBL Subtypes. Blood, 2020, 136, 35-36.	1.4	0
67	Comparison of MGUS Prevalence By Race and Family History Risk Groups Using a High Sensitivity Screening Method (MASS-FIX). Blood, 2020, 136, 40-41.	1.4	1
68	Body Mass Index and Clinical Factors Associated with Monoclonal Gammopathy of Undetermined Significance (MGUS) Progression in Olmsted County, Minnesota. Blood, 2020, 136, 15-16.	1.4	0
69	Prevalence of Familial Plasma Cell Disorders in Patients with Multiple Myeloma. Blood, 2020, 136, 1-2.	1.4	0
70	Association of elevated serumfree light chains with chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood Cancer Journal, 2019, 9, 59.	6.2	9
71	Genetic predictors of chemotherapy-related amenorrhea inÂwomen with breast cancer. Fertility and Sterility, 2019, 112, 731-739.e1.	1.0	10
72	Associations of mammographic breast density with breast stem cell marker-defined breast cancer subtypes. Cancer Causes and Control, 2019, 30, 1103-1111.	1.8	7

#	Article	IF	CITATIONS
73	Automated volumetric breast density measures: differential change between breasts in women with and without breast cancer. Breast Cancer Research, 2019, 21, 118.	5.0	13
74	Accuracy of self-reported cancer treatment data in young breast cancer survivors. Journal of Patient-Reported Outcomes, 2019, 3, 24.	1.9	5
75	Two truncating variants in FANCC and breast cancer risk. Scientific Reports, 2019, 9, 12524.	3.3	5
76	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	12.8	88
77	Joint association of mammographic density adjusted for age and body mass index and polygenic risk score with breast cancer risk. Breast Cancer Research, 2019, 21, 68.	5.0	31
78	Discussions of Dense Breasts, Breast Cancer Risk, and Screening Choices in 2019. JAMA - Journal of the American Medical Association, 2019, 322, 69.	7.4	15
79	Longitudinal Changes in Volumetric Breast Density in Healthy Women across the Menopausal Transition. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1324-1330.	2.5	17
80	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 2019, 10, 1741.	12.8	90
81	Impact of short-term low-dose tamoxifen on molecular breast imaging background parenchymal uptake: a pilot study. Breast Cancer Research, 2019, 21, 38.	5.0	11
82	Body mass index, mammographic density, and breast cancer risk by estrogen receptor subtype. Breast Cancer Research, 2019, 21, 48.	5.0	52
83	Genome-wide association study of germline variants and breast cancer-specific mortality. British Journal of Cancer, 2019, 120, 647-657.	6.4	52
84	Incidence of AL Amyloidosis in Olmsted County, Minnesota, 1990 through 2015. Mayo Clinic Proceedings, 2019, 94, 465-471.	3.0	87
85	Breast Cancer Classification using Deep Transfer Learning on Structured Healthcare Data. , 2019, , .		9
86	Behavioral and psychological impact of returning breast density results to Latinas: study protocol for a randomized clinical trial. Trials, 2019, 20, 744.	1.6	5
87	Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement. Blood Cancer Journal, 2019, 9, 102.	6.2	57
88	Risk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristics. Leukemia, 2019, 33, 499-507.	7.2	9
89	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. American Journal of Human Genetics, 2019, 104, 21-34.	6.2	711
90	Molecular mechanisms linking high body mass index to breast cancer etiology in post-menopausal breast tumor and tumor-adjacent tissues. Breast Cancer Research and Treatment, 2019, 173, 667-677.	2.5	19

#	Article	IF	CITATIONS
91	Radiomic Phenotypes of Mammographic Parenchymal Complexity: Toward Augmenting Breast Density in Breast Cancer Risk Assessment. Radiology, 2019, 290, 41-49.	7.3	63
92	Association between a Polygenic Risk Score for Multiple Myeloma Risk and Overall Survival. Blood, 2019, 134, 4366-4366.	1.4	0
93	Germline Variation Predicts Treatment Response in Multiple Myeloma. Blood, 2019, 134, 4397-4397.	1.4	Ο
94	The CCND1 870G Risk Allele Is Enriched in African Individuals with Plasma Cell Dyscrasias. Blood, 2019, 134, 4362-4362.	1.4	0
95	Tumor Mutational Load and Germline Polygenic Risk Score Predicts Time-to-First Treatment in Chronic Lymphocytic Leukemia (CLL) and High-Count Monoclonal B Cell Lymphocytosis (MBL). Blood, 2019, 134, 852-852.	1.4	Ο
96	Stroma modifies relationships between risk factor exposure and age-related epithelial involution in benign breast. Modern Pathology, 2018, 31, 1085-1096.	5.5	9
97	Does mammographic density mediate risk factor associations with breast cancer? An analysis by tumor characteristics. Breast Cancer Research and Treatment, 2018, 170, 129-141.	2.5	11
98	Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood, 2018, 131, 2541-2551.	1.4	21
99	Prenatal diethylstilbestrol exposure and mammographic density. International Journal of Cancer, 2018, 143, 1374-1378.	5.1	3
100	Common Genetic Variation and Breast Cancer Risk—Past, Present, and Future. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 380-394.	2.5	108
101	Joint associations of a polygenic risk score and environmental risk factors for breast cancer in the Breast Cancer Association Consortium. International Journal of Epidemiology, 2018, 47, 526-536.	1.9	88
102	Germline Lysine-Specific Demethylase 1 (<i>LSD1/KDM1A</i>) Mutations Confer Susceptibility to Multiple Myeloma. Cancer Research, 2018, 78, 2747-2759.	0.9	56
103	Model for Predicting Breast Cancer Risk in Women With Atypical Hyperplasia. Journal of Clinical Oncology, 2018, 36, 1840-1846.	1.6	22
104	Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestry. Blood Cancer Journal, 2018, 8, 96.	6.2	47
105	Evaluation of 2 breast cancer risk models in a benign breast disease cohort. Cancer, 2018, 124, 3319-3328.	4.1	7
106	Quantitative background parenchymal uptake on molecular breast imaging and breast cancer risk: a case-control study. Breast Cancer Research, 2018, 20, 46.	5.0	12
107	Automated and Clinical Breast Imaging Reporting and Data System Density Measures Predict Risk for Screen-Detected and Interval Cancers. Annals of Internal Medicine, 2018, 168, 757-765.	3.9	56
108	The National Cancer Institute Cohort Consortium: An International Pooling Collaboration of 58 Cohorts from 20 Countries. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 1307-1319.	2.5	18

#	Article	IF	CITATIONS
109	The association of mammographic density with risk of contralateral breast cancer and change in density with treatment in the WECARE study. Breast Cancer Research, 2018, 20, 23.	5.0	24
110	Identification of nine new susceptibility loci for endometrial cancer. Nature Communications, 2018, 9, 3166.	12.8	178
111	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. Nature Genetics, 2018, 50, 968-978.	21.4	184
112	Polygenic risk score for breast cancer in high-risk women Journal of Clinical Oncology, 2018, 36, 1508-1508.	1.6	11
113	Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma risk. PLoS Genetics, 2018, 14, e1007111.	3.5	30
114	Accuracy of self-reported chemotherapy regimens in young breast cancer survivors Journal of Clinical Oncology, 2018, 36, e22143-e22143.	1.6	0
115	Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Chronic Lymphocytic Leukemia (CLL) Driver Genes: Risk of CLL and Monoclonal B-Cell Lymphocytosis (MBL). Blood, 2018, 132, 3116-3116.	1.4	0
116	Genomic Abnormalities Among African Individuals with Monoclonal Gammopathies Using Calculated Ancestry. Blood, 2018, 132, 4458-4458.	1.4	0
117	Large-Scale Linkage Analysis of Multiple Myeloma (MM) and Monoclonal Gammopathy of Undetermined Significance (MGUS) Families. Blood, 2018, 132, 4501-4501.	1.4	0
118	Longitudinal Changes in Volumetric Breast Density with Tamoxifen and Aromatase Inhibitors. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 930-937.	2.5	37
119	Interaction of mammographic breast density with menopausal status and postmenopausal hormone use in relation to the risk of aggressive breast cancer subtypes. Breast Cancer Research and Treatment, 2017, 165, 421-431.	2.5	11
120	Mammographic breast density and risk of breast cancer in women with atypical hyperplasia: an observational cohort study from the Mayo Clinic Benign Breast Disease (BBD) cohort. BMC Cancer, 2017, 17, 84.	2.6	23
121	Association analysis identifies 65 new breast cancer risk loci. Nature, 2017, 551, 92-94.	27.8	1,099
122	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	21.4	289
123	NanoString-based breast cancer risk prediction for women with sclerosing adenosis. Breast Cancer Research and Treatment, 2017, 166, 641-650.	2.5	10
124	Body mass index and breast cancer survival: a Mendelian randomization analysis. International Journal of Epidemiology, 2017, 46, 1814-1822.	1.9	45
125	Combining quantitative and qualitative breast density measures to assess breast cancer risk. Breast Cancer Research, 2017, 19, 97.	5.0	35
126	Tissue-based associations of mammographic breast density with breast stem cell markers. Breast Cancer Research, 2017, 19, 100.	5.0	7

#	Article	IF	CITATIONS
127	Alcohol consumption and breast tumor gene expression. Breast Cancer Research, 2017, 19, 108.	5.0	23
128	Association between mammographic breast density and histologic features of benign breast disease. Breast Cancer Research, 2017, 19, 134.	5.0	24
129	Mammographic density and ageing: A collaborative pooled analysis of cross-sectional data from 22 countries worldwide. PLoS Medicine, 2017, 14, e1002335.	8.4	108
130	Using Breast Cancer Risk Associated Polymorphisms to Identify Women for Breast Cancer Chemoprevention. PLoS ONE, 2017, 12, e0168601.	2.5	16
131	Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. Oncotarget, 2016, 7, 80140-80163.	1.8	31
132	Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus. PLoS ONE, 2016, 11, e0160316.	2.5	12
133	<i>PALB2</i> , <i>CHEK2</i> and <i>ATM</i> rare variants and cancer risk: data from COGS. Journal of Medical Genetics, 2016, 53, 800-811.	3.2	174
134	Mammographic texture and risk of breast cancer by tumor type and estrogen receptor status. Breast Cancer Research, 2016, 18, 122.	5.0	35
135	Unsupervised Deep Learning Applied to Breast Density Segmentation and Mammographic Risk Scoring. IEEE Transactions on Medical Imaging, 2016, 35, 1322-1331.	8.9	360
136	Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypes. Breast Cancer Research and Treatment, 2016, 157, 117-131.	2.5	18
137	A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1609-1618.	2.5	18
138	Breast cancer risk by the extent and type of atypical hyperplasia. Cancer, 2016, 122, 3087-3088.	4.1	10
139	Extent of atypical hyperplasia stratifies breast cancer risk in 2 independent cohorts of women. Cancer, 2016, 122, 2971-2978.	4.1	48
140	Breast cancer risk prediction using a clinical risk model and polygenic risk score. Breast Cancer Research and Treatment, 2016, 159, 513-525.	2.5	129
141	rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk. Scientific Reports, 2016, 6, 36874.	3.3	2
142	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discovery, 2016, 6, 1052-1067.	9.4	157
143	Mammographic density is the main correlate of tumors detected on ultrasound but not on mammography. International Journal of Cancer, 2016, 139, 1967-1974.	5.1	19
144	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375.	12.8	93

#	Article	IF	CITATIONS
145	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	12.8	78
146	Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). Scientific Reports, 2016, 6, 32512.	3.3	19
147	Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. Nature Communications, 2016, 7, 10933.	12.8	94
148	Mammographic density assessed on paired raw and processed digital images and on paired screen-film and digital images across three mammography systems. Breast Cancer Research, 2016, 18, 130.	5.0	17
149	Age- and Tumor Subtype–Specific Breast Cancer Risk Estimates for <i>CHEK2</i> *1100delC Carriers. Journal of Clinical Oncology, 2016, 34, 2750-2760.	1.6	152
150	Breast Density: More Than Meets the Eye. Journal of the National Cancer Institute, 2016, 108, djw128.	6.3	6
151	Background parenchymal uptake on molecular breast imaging as a breast cancer risk factor: a case-control study. Breast Cancer Research, 2016, 18, 42.	5.0	19
152	International Consortium on Mammographic Density: Methodology and population diversity captured across 22 countries. Cancer Epidemiology, 2016, 40, 141-151.	1.9	19
153	Personalizing Aspirin Use for Targeted Breast Cancer Chemoprevention in Postmenopausal Women. Mayo Clinic Proceedings, 2016, 91, 71-80.	3.0	20
154	Natural history of age-related lobular involution and impact on breast cancer risk. Breast Cancer Research and Treatment, 2016, 155, 423-430.	2.5	29
155	No evidence that protein truncating variants in <i>BRIP1</i> are associated with breast cancer risk: implications for gene panel testing. Journal of Medical Genetics, 2016, 53, 298-309.	3.2	94
156	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386.	21.4	125
157	Comparison of Clinical and Automated Breast Density Measurements: Implications for Risk Prediction and Supplemental Screening. Radiology, 2016, 279, 710-719.	7.3	145
158	Skin Cancers Among Chronic Lymphocytic Leukemia (CLL) Patients - the Effect of UV Radiation and CLL Clinical Characteristics. Blood, 2016, 128, 4772-4772.	1.4	4
159	Risk of Monoclonal Gammopathy of Undetermined Significance in First-Degree Relatives of Multiple Myeloma Cases By Cytogenetic Subtype. Blood, 2016, 128, 4425-4425.	1.4	0
160	Common germline polymorphisms associated with breast cancer-specific survival. Breast Cancer Research, 2015, 17, 58.	5.0	26
161	A comprehensive evaluation of interaction between genetic variants and use of menopausal hormone therapy on mammographic density. Breast Cancer Research, 2015, 17, 110.	5.0	19
162	Whole Genome Sequence of Multiple Myeloma-Prone C57BL/KaLwRij Mouse Strain Suggests the Origin of Disease Involves Multiple Cell Types. PLoS ONE, 2015, 10, e0127828.	2.5	26

#	Article	IF	CITATIONS
163	Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants. Journal of the National Cancer Institute, 2015, 107, .	6.3	428
164	Awareness of Breast Density and Its Impact on Breast Cancer Detection and Risk. Journal of Clinical Oncology, 2015, 33, 1143-1150.	1.6	96
165	A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2. Breast Cancer Research and Treatment, 2015, 149, 517-523.	2.5	22
166	Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer. Journal of Clinical Oncology, 2015, 33, 304-311.	1.6	521
167	Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. Human Molecular Genetics, 2015, 24, 2966-2984.	2.9	40
168	Model for Individualized Prediction of Breast Cancer Risk After a Benign Breast Biopsy. Journal of Clinical Oncology, 2015, 33, 923-929.	1.6	51
169	Fine-Scale Mapping of the 5q11.2 Breast Cancer Locus Reveals at Least Three Independent Risk Variants Regulating MAP3K1. American Journal of Human Genetics, 2015, 96, 5-20.	6.2	76
170	Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer. Carcinogenesis, 2015, 36, 256-271.	2.8	14
171	Cenome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nature Genetics, 2015, 47, 373-380.	21.4	513
172	The Contributions of Breast Density and Common Genetic Variation to Breast Cancer Risk. Journal of the National Cancer Institute, 2015, 107, .	6.3	174
173	Effect of Menstrual Cycle Phase on Background Parenchymal Uptake at Molecular Breast Imaging. Academic Radiology, 2015, 22, 1147-1156.	2.5	14
174	Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. Nature Communications, 2015, 6, 7539.	12.8	38
175	Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. American Journal of Human Genetics, 2015, 97, 22-34.	6.2	37
176	Identification of Novel Genetic Markers of Breast Cancer Survival. Journal of the National Cancer Institute, 2015, 107, .	6.3	56
177	Mammographic density and breast cancer risk by family history in women of white and Asian ancestry. Cancer Causes and Control, 2015, 26, 621-626.	1.8	17
178	Background Parenchymal Uptake During Molecular Breast Imaging and Associated Clinical Factors. American Journal of Roentgenology, 2015, 204, W363-W370.	2.2	24
179	Dense and Nondense Mammographic Area and Risk of Breast Cancer by Age and Tumor Characteristics. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 798-809.	2.5	42
180	Novel Associations between Common Breast Cancer Susceptibility Variants and Risk-Predicting Mammographic Density Measures. Cancer Research, 2015, 75, 2457-2467.	0.9	55

#	Article	IF	CITATIONS
181	Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis. BMC Medicine, 2015, 13, 156.	5.5	51
182	The association of copy number variation and percent mammographic density. BMC Research Notes, 2015, 8, 297.	1.4	2
183	Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. Journal of the National Cancer Institute, 2015, 107, djv219.	6.3	99
184	Breast Density and Benign Breast Disease: Risk Assessment to Identify Women at High Risk of Breast Cancer. Journal of Clinical Oncology, 2015, 33, 3137-3143.	1.6	170
185	Postmenopausal mammographic breast density and subsequent breast cancer risk according to selected tissue markers. British Journal of Cancer, 2015, 113, 1104-1113.	6.4	20
186	Complex fibroadenoma and breast cancer risk: a Mayo Clinic Benign Breast Disease Cohort Study. Breast Cancer Research and Treatment, 2015, 153, 397-405.	2.5	61
187	Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. Human Molecular Genetics, 2015, 24, 285-298.	2.9	38
188	MicroRNA Related Polymorphisms and Breast Cancer Risk. PLoS ONE, 2014, 9, e109973.	2.5	49
189	Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. Human Molecular Genetics, 2014, 23, 6096-6111.	2.9	53
190	Methods for Assessing and Representing Mammographic Density: An Analysis of 4 Case-Control Studies. American Journal of Epidemiology, 2014, 179, 236-244.	3.4	8
191	A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46 450 cases and 42 461 controls from the breast cancer association consortium. Human Molecular Genetics, 2014, 23, 1934-1946.	2.9	32
192	Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. Carcinogenesis, 2014, 35, 1012-1019.	2.8	145
193	Genome-wide association study identifies multiple loci associated with both mammographic density and breast cancer risk. Nature Communications, 2014, 5, 5303.	12.8	109
194	Mammographic Density Phenotypes and Risk of Breast Cancer: A Meta-analysis. Journal of the National Cancer Institute, 2014, 106, .	6.3	261
195	Automated Percentage of Breast Density Measurements for Full-field Digital Mammography Applications. Academic Radiology, 2014, 21, 958-970.	2.5	15
196	Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. Nature Communications, 2014, 5, 4999.	12.8	105
197	Mammographic texture resemblance generalizes as an independent risk factor for breast cancer. Breast Cancer Research, 2014, 16, R37.	5.0	31
198	Breast Density and Breast Cancer Risk: A Practical Review. Mayo Clinic Proceedings, 2014, 89, 548-557.	3.0	84

#	Article	IF	CITATIONS
199	Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. Breast Cancer Research, 2014, 16, R51.	5.0	14
200	Comparison of percent density from raw and processed full-field digital mammography data. Breast Cancer Research, 2013, 15, R1.	5.0	32
201	Mammographic Density: Potential as a Risk Factor and Surrogate Marker in the Clinical Setting. Current Breast Cancer Reports, 2013, 5, 183-193.	1.0	6
202	A new statistic for identifying batch effects in high-throughput genomic data that uses guided principal component analysis. Bioinformatics, 2013, 29, 2877-2883.	4.1	118
203	Benign Breast Disease, Mammographic Breast Density, and the Risk of Breast Cancer. Journal of the National Cancer Institute, 2013, 105, 1043-1049.	6.3	99
204	Fine-Scale Mapping of the FGFR2 Breast Cancer Risk Locus: Putative Functional Variants Differentially Bind FOXA1 and E2F1. American Journal of Human Genetics, 2013, 93, 1046-1060.	6.2	98
205	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	21.4	493
206	Genome-wide association studies identify four ER negative–specific breast cancer risk loci. Nature Genetics, 2013, 45, 392-398.	21.4	374
207	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nature Genetics, 2013, 45, 353-361.	21.4	960
208	Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nature Genetics, 2013, 45, 868-876.	21.4	179
209	Genetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome–wide interaction study. Endocrine-Related Cancer, 2013, 20, 875-887.	3.1	26
210	Mammographic Breast Density Response to Aromatase Inhibition. Clinical Cancer Research, 2013, 19, 2144-2153.	7.0	30
211	Differences in the distribution of cytogenetic subtypes between multiple myeloma patients with and without a family history of monoclonal gammopathy and multiple myeloma. European Journal of Haematology, 2013, 91, 193-195.	2.2	2
212	Mammographic density and risk of breast cancer by age and tumor characteristics. Breast Cancer Research, 2013, 15, R104.	5.0	146
213	Deletion Of Samsn1 Underlies Genetic Susceptibility To Monoclonal Gammopathy Of Undetermined Significance (MGUS) In Mice. Blood, 2013, 122, 397-397.	1.4	1
214	A Meta-Analysis Of Genome-Wide Association Studies Of Multiple Myeloma In Cases and Controls Of European Origin Identifies a Risk Locus In 12q23.1. Blood, 2013, 122, 3111-3111.	1.4	2
215	Common Breast Cancer Susceptibility Variants in <i>LSP1</i> and <i>RAD51L1</i> Are Associated with Mammographic Density Measures that Predict Breast Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1156-1166.	2.5	101
216	Identification of a novel percent mammographic density locus at 12q24. Human Molecular Genetics, 2012, 21, 3299-3305.	2.9	31

#	Article	IF	CITATIONS
217	19p13.1 Is a Triple-Negative–Specific Breast Cancer Susceptibility Locus. Cancer Research, 2012, 72, 1795-1803.	0.9	100
218	Mammographic Breast Density and Breast Cancer: Evidence of a Shared Genetic Basis. Cancer Research, 2012, 72, 1478-1484.	0.9	54
219	A Novel Automated Mammographic Density Measure and Breast †Cancer Risk. Journal of the National Cancer Institute, 2012, 104, 1028-1037.	6.3	67
220	The influence of mammogram acquisition on the mammographic density and breast cancer association in the mayo mammography health study cohort. Breast Cancer Research, 2012, 14, R147.	5.0	47
221	A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Human Molecular Genetics, 2012, 21, 5373-5384.	2.9	168
222	Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics. Blood, 2012, 119, 5359-5366.	1.4	68
223	Mammographic density, parity and age at first birth, and risk of breast cancer: an analysis of four case–control studies. Breast Cancer Research and Treatment, 2012, 132, 1163-1171.	2.5	43
224	Increased prevalence of light chain monoclonal gammopathy of undetermined significance (<scp>LC</scp> â€ <scp>MGUS</scp>) in firstâ€degree relatives of individuals with multiple myeloma. British Journal of Haematology, 2012, 157, 472-475.	2.5	12
225	No evidence for association of inherited variation in genes involved in mitosis and percent mammographic density. Breast Cancer Research, 2012, 14, R7.	5.0	3
226	Mammographic density and risk of breast cancer by adiposity: An analysis of four case ontrol studies. International Journal of Cancer, 2012, 130, 1915-1924.	5.1	30
227	Tissue composition of mammographically dense and non-dense breast tissue. Breast Cancer Research and Treatment, 2012, 131, 267-275.	2.5	72
228	Differences in the Distribution of Cytogenetic Subtypes Between Multiple Myeloma Patients with and without a History of Familial MGUS and Multiple Myeloma. Blood, 2012, 120, 4000-4000.	1.4	0
229	Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies. Journal of the National Cancer Institute, 2011, 103, 250-263.	6.3	596
230	A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor–negative breast cancer. Nature Genetics, 2011, 43, 1210-1214.	21.4	279
231	Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL. Blood, 2011, 117, 1911-1916.	1.4	118
232	Common variants in ZNF365 are associated with both mammographic density and breast cancer risk. Nature Genetics, 2011, 43, 185-187.	21.4	109
233	Aromatase immunoreactivity is increased in mammographically dense regions of the breast. Breast Cancer Research and Treatment, 2011, 125, 243-252.	2.5	48
234	Mammographic Breast Density and Subsequent Risk of Breast Cancer in Postmenopausal Women According to Tumor Characteristics. Journal of the National Cancer Institute, 2011, 103, 1179-1189.	6.3	192

#	Article	IF	CITATIONS
235	Prevalence of MBL Increases Over Time In Relatives of CLL Families,. Blood, 2011, 118, 3881-3881.	1.4	0
236	Mammographic density does not differ between unaffected BRCA1/2 mutation carriers and women at low-to-average risk of breast cancer. Breast Cancer Research and Treatment, 2010, 123, 245-255.	2.5	33
237	Common occurrence of monoclonal Bâ€cell lymphocytosis among members of highâ€risk CLL families. British Journal of Haematology, 2010, 151, 152-158.	2.5	61
238	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor–negative breast cancer in the general population. Nature Genetics, 2010, 42, 885-892.	21.4	309
239	Breast Cancer Risk by Breast Density, Menopause, and Postmenopausal Hormone Therapy Use. Journal of Clinical Oncology, 2010, 28, 3830-3837.	1.6	188
240	Association Between Mammographic Density and Age-Related Lobular Involution of the Breast. Journal of Clinical Oncology, 2010, 28, 2207-2212.	1.6	84
241	Independent Association of Lobular Involution and Mammographic Breast Density With Breast Cancer Risk. Journal of the National Cancer Institute, 2010, 102, 1716-1723.	6.3	66
242	Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer. Breast Cancer Research, 2010, 12, R19.	5.0	16
243	Texture Features from Mammographic Images and Risk of Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 837-845.	2.5	121
244	Prevention of Breast Cancer in Postmenopausal Women: Approaches to Estimating and Reducing Risk. Journal of the National Cancer Institute, 2009, 101, 384-398.	6.3	226
245	Lobular involution: localized phenomenon or field effect?. Breast Cancer Research and Treatment, 2009, 117, 193-196.	2.5	20
246	Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. Blood, 2009, 114, 785-790.	1.4	127
247	Breast cancer risk in women with radial scars in benign breast biopsies. Breast Cancer Research and Treatment, 2008, 108, 167-174.	2.5	83
248	Dietary patterns and breast density in the Minnesota Breast Cancer Family Study. Cancer Causes and Control, 2008, 19, 481-489.	1.8	17
249	Can genes for mammographic density inform cancer aetiology?. Nature Reviews Cancer, 2008, 8, 812-823.	28.4	40
250	Genetic variation in stromal proteins decorin and lumican with breast cancer: investigations in two case-control studies. Breast Cancer Research, 2008, 10, R98.	5.0	41
251	Age-specific Trends in Mammographic Density: The Minnesota Breast Cancer Family Study. American Journal of Epidemiology, 2008, 167, 1027-1036.	3.4	88
252	Association of Mammographic Density with the Pathology of Subsequent Breast Cancer among Postmenopausal Women. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 872-879.	2.5	52

#	Article	IF	CITATIONS
253	Association of Genetic Variation in Genes Implicated in the β-Catenin Destruction Complex with Risk of Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 2101-2108.	2.5	67
254	Assessment of the Accuracy of the Gail Model in Women With Atypical Hyperplasia. Journal of Clinical Oncology, 2008, 26, 5374-5379.	1.6	94
255	Heterogeneity of Breast Cancer Associations with Five Susceptibility Loci by Clinical and Pathological Characteristics. PLoS Genetics, 2008, 4, e1000054.	3.5	315
256	Mediterranean Diet and Breast Density in the Minnesota Breast Cancer Family Study. Nutrition and Cancer, 2008, 60, 703-709.	2.0	24
257	An Automated Approach for Estimation of Breast Density. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 3090-3097.	2.5	67
258	Increased Risk of Monoclonal Gammopathy in First-Degree Relatives of Patients with Multiple Myeloma or Monoclonal Gammopathy of Undetermined Significance Blood, 2008, 112, 1672-1672.	1.4	0
259	Longitudinal Trends in Mammographic Percent Density and Breast Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 921-928.	2.5	118
260	Mammographic Breast Density as a General Marker of Breast Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 43-49.	2.5	181
261	Strong Evidence of a Genetic Determinant for Mammographic Density, a Major Risk Factor for Breast Cancer. Cancer Research, 2007, 67, 8412-8418.	0.9	69
262	Response: Re: Age-Related Lobular Involution and Risk of Breast Cancer. Journal of the National Cancer Institute, 2007, 99, 572-572.	6.3	0
263	Mammographic density, breast cancer risk and risk prediction. Breast Cancer Research, 2007, 9, 217.	5.0	270
264	Association of diabetes with mammographic breast density and breast cancer in the Minnesota breast cancer family study. Cancer Causes and Control, 2007, 18, 505-515.	1.8	25
265	Age-Related Lobular Involution and Risk of Breast Cancer. Journal of the National Cancer Institute, 2006, 98, 1600-1607.	6.3	218
266	Alcohol intake in adolescence and mammographic density. International Journal of Cancer, 2005, 117, 837-841.	5.1	21
267	Prenatal and Perinatal Correlates of Adult Mammographic Breast Density. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1502-1508.	2.5	42
268	Benign Breast Disease and the Risk of Breast Cancer. New England Journal of Medicine, 2005, 353, 229-237.	27.0	785
269	Clinical Characteristics of Familial vs. Sporadic non-Hodgkin lymphoma in Patients Diagnosed at The Mayo Clinic (1986 – 2000). Leukemia and Lymphoma, 2004, 45, 929-935.	1.3	3
270	Association of Parity and Ovarian Cancer Risk by Family History of Breast or Ovarian Cancer in a Population-Based Study of Postmenopausal Women. Epidemiology, 2002, 13, 66-71.	2.7	34

#	Article	IF	CITATIONS
271	Case-control study of increased mammographic breast density response to hormone replacement therapy. Cancer Epidemiology Biomarkers and Prevention, 2002, 11, 1382-8.	2.5	40
272	Investigation of an interaction of alcohol intake and family history on breast cancer risk in the Minnesota Breast Cancer Family Study. Cancer, 2001, 92, 240-248.	4.1	40
273	Association of mammographically defined percent breast density with epidemiologic risk factors for breast cancer (United States). Cancer Causes and Control, 2000, 11, 653-662.	1.8	311
274	An investigation of the effects of mammographic acquisition parameters on a semiautomated quantitative measure of breast cancer risk. Journal of Digital Imaging, 2000, 13, 186-188.	2.9	3
275	Genetic anticipation and breast cancer: a prospective followâ€up study. Breast Cancer Research and Treatment, 1999, 55, 21-28.	2.5	14
276	Familial correlation of dietary intakes among postmenopausal women. , 1998, 15, 553-563.		13
277	Evaluation of potential sources of bias in a genetic epidemiologic study of breast cancer. Genetic Epidemiology, 1997, 14, 85-95.	1.3	11
278	Segregation analysis of breast cancer: A comparison of type-dependent age-at-onset versus type-dependent susceptibility models. , 1996, 13, 317-328.		4
279	Does a Multiple Myeloma Polygenic Risk Score Predict Overall Survival of Myeloma Patients?. Cancer Epidemiology Biomarkers and Prevention, 0, , .	2.5	2